Results 51 to 60 of about 28,829 (241)

Host carbon sources modulate cell wall architecture, drug resistance and virulence in a fungal pathogen [PDF]

, 2012
The survival of all microbes depends upon their ability to respond to environmental challenges. To establish infection, pathogens such as Candida albicans must mount effective stress responses to counter host defences while adapting to dynamic changes in
Adya, Ashok K., Brand, Alexandra C., Brown, Alistair J. P., Ene, Iuliana V., Gow, Neil A. R., MacCallum, Donna M., Wehmeier, Silvia   +6 more
core   +3 more sources

Disseminated candidemia refractory to caspofungin therapy in an infant with extremely low birth weight

Journal of the Formosan Medical Association, 2012
Systemic fungal infections have high morbidity and mortality rates in neonates, especially neonates with an extremely low birth weight (ELBW). Here, we describe a 21-day-old ELBW female infant with an amphotericin B-unresponsive congenital Candida ...
Meng-Ju Li, Po-Ren Hsueh, Chun-Yi Lu, Hung-Chieh Chou, Ping-Ing Lee, Luan-Yin Chang, Li-Min Huang   +6 more
doaj   +1 more source

Biofilm-forming capability of highly virulent, multidrug-resistant Candida auris [PDF]

, 2017
The emerging multidrug-resistant yeast pathogen Candida auris has attracted considerable attention as a source of healthcare–associated infections. We report that this highly virulent yeast has the capacity to form antifungal resistant biofilms sensitive
Borman, Andrew, Johnson, Elizabeth M., Kean, Ryan, Ramage, Gordon, Rautemaa-Richardson, Riina, Richardson, Malcolm D., Sherry, Leighann   +6 more
core   +4 more sources

Pitfalls associated with the use of molecular diagnostic panels in the diagnosis of cryptococcal meningitis [PDF]

, 2017
We report the case of a kidney transplantation patient on chronic immunosuppressive therapy presenting with subacute meningitis. The final diagnosis of cryptococcal meningitis was delayed due to 2 false-negative cryptococcal results on a molecular ...
Burnham, Carey-Ann, Dubberke, Erik, Franklin, Alexander, Lainhart, William, O\u27Halloran, Jane A, Powderly, William   +5 more
core   +2 more sources

Candida auris, what do paediatricians need to know? [PDF]

, 2018
AW is supported by the Wellcome Trust Strategic Award (grant 097377) and the MRC Centre for Medical Mycology (grant MR/N006364/1) at the University of Aberdeen.Peer reviewedPublisher ...
Warris, Adilia
core   +1 more source

Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis

Antimicrobial Agents and Chemotherapy
Rezafungin is a long-acting, intravenously administered echinocandin for the treatment of candidemia and invasive candidiasis (IC). Non-inferiority of rezafungin vs caspofungin for the treatment of adults with candidemia and/or IC was demonstrated in the
J. B. Locke, C. Pillar, M. Castanheira, C. Carvalhaes, David R. Andes, J. Aram, Christina Andrzejewski, Ken Bartizal, Anita F Das, T. Sandison, George R Thompson, Peter G. Pappas   +11 more
semanticscholar   +1 more source

Efficacy and safety of caspofungin for patients with hepatic insufficiency

BMC Infectious Diseases, 2022
Background To observe the changes of hepatic function and efficacy of conventional dosage of caspofungin in the treatment of patients with different Child–Pugh scores.
Xiaoyun Ran, Pengfei Wang, An Zhang, Binfei Tang   +3 more
doaj   +1 more source

Oma1 Links Mitochondrial Protein Quality Control and TOR Signaling To Modulate Physiological Plasticity and Cellular Stress Responses [PDF]

, 2016
ACKNOWLEDGMENTS We thank Dennis Winge (University of Utah) and the members of the Khalimonchuk laboratory for critical comments. We also thank Christoph Schuller (University of Natural Resources, Austria) and Paul Herman (Ohio State University) for ...
Barrientos, Antoni, Bohovych, Iryna, Brown, Alistair J.P., Christianson, Sara, Fangman, Teresa, Kastora, Stavroula, Khalimonchuk, Oleh, Kim, Heejeong, Lee, Jaekwon, Topil, Danelle, Zhou, You J.   +10 more
core   +2 more sources

Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials

Critical Care
Rezafungin is an echinocandin approved in the US and EU to treat candidaemia and/or invasive candidiasis. This post-hoc, pooled analysis of the Phase 2 STRIVE and Phase 3 ReSTORE trials assessed rezafungin versus caspofungin in patients with candidaemia ...
P. Honoré, M. Girardis, Marin H. Kollef, Oliver A. Cornely, George R Thompson, M. Bassetti, Á. Soriano, Haihui Huang, Jose A Vazquez, B. Kullberg, Peter G. Pappas, Nick Manamley, T. Sandison, J. Pullman, S. Nseir   +14 more
semanticscholar   +1 more source

An on-line solid phase extraction procedure for the routine quantification of caspofungin by liquid chromatography-tandem mass spectrometry [PDF]

, 2012
Background: Extensive sets of data are required to investigate the potential use of a therapeutic drug monitoring with individualization of dosage of the antimycotic compound caspofungin.
Kirchhoff, Fabian, Maier, Barbara, Ostermann, Helmut, Rieger, Christina, Spoehrer, Ute, Vogeser, Michael   +5 more
core   +1 more source